Rinvoq can increase the risk of certain health conditions, including cancers like lymphoma or skin cancer. This risk increases for people who smoke and these individuals may be more susceptible to ...

Last month, the FDA added a boxed warning to Xeljanz’ label for increased risk of potentially ... for serious infections, cancer and blood clots on its label. Rinvoq hasn’t sidestepped those ...

GI perforation risk (eg, history of diverticulitis); monitor and evaluate promptly if new onset abdominal pain occurs. Perform periodic skin exam in those with skin cancer risk. Update ...

AbbVie executives say the company’s immunology drugs Skyrizi and Rinvoq are expanding their reach in the inflammatory bowel disease (IBD) as the market for Humira biosimilars heats up.

The EU regulator has cleared Rinvoq (upadacitinib) as an oral treatment for moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older, either with or without topical ...

The decline was offset by sales of its newer arthritis drugs Skyrizi, which soared by 57% to $3.78 billion, and Rinvoq, which logged a 46% gain to $1.83 billion. Chief Executive Robert Michael ...

AbbVie expects the combined sales (risk-adjusted) of Skyrizi and Rinvoq to be more than $27 billion ... States for nonsquamous non-small cell lung cancer.